

Pranshu Bansal, M.D.

CURRICULUM VITAE

Ironwood Cancer & Research Centers, A Division of
Ironwood Physicians, PC

WORK EXPERIENCE

Ironwood Physicians, PC

Staff Physician - New Mexico Cancer Center, Albuquerque, NM

Clinical Assistant Professor Burrell College of Osteopathic Medicine, Las Cruces, NM

Director of clinical research/Phase 2/3 clinical trial program at New Mexico Cancer Center, Albuquerque NM

Board Member New Mexico Cancer Care Alliance- Director of Research at New Mexico Cancer Center, NM

Research Associate- Dr Yanis Bumber Lab/ University Of New Mexico, Albuquerque NM
worked on “role of Musashi2 in lung cancer progression and resistance to chemotherapy”

Lab Research Assistant- Dr Robert Hromas Lab/ University of New Mexico, Albuquerque, NM, worked on “role of histone deacetylase in peripheral T Cell leukemia”

Visiting Medical Student- University of New Mexico, Department of Internal Medicine, Albuquerque, NM

Visiting Medical Student- National Institute of Health, Department of Internal Medicine, Division of Endocrinology/Metabolism, Bethesda MD

POST GRADUATE TRAINING

University of New Mexico, Albuquerque, NM

Fellowship in Hematology/Oncology
University of Missouri Hospital and Clinics, Columbia, MO
Residency in Internal Medicine

EDUCATION

Vardhman Mahavir Medical College and Safdarjung Hospital
New Delhi- India
M.B.B.S. (Bachelor of Medicine, Bachelor of Surgery)

BOARD CERTIFICATION

American Board of Internal Medicine- Hematology
American Board of Internal Medicine- Oncology
American Board of Internal medicine
ECFMG Certification

AWARDS/HONORS

Distinction in Professional I- Physiology
State Winner National Science Olympiad in Chemistry, India

PROFESSIONAL MEMBERSHIPS

HLH society of America
American Association for Cancer Research
American Society of Clinical Oncology
American Society of Hematology
Resident Council- University of New Mexico
American College of Physicians
Quality Improvement Committee- University of Missouri
Indian Medical Association
Indian Red Cross

PUBLICATIONS

Articles in peer-reviewed journals

Aggarwal S, Singh H, **Bansal P**, Goyal A, Saminder Singh K.. Training In Clinical Research in India. Indian Journal of Community Medicine. July 2010. PMID 21031122

Loo E, **Bansal P**, Cherukuri D, Arana Yi C Isodicentric Philadelphia chromosome: an uncommon chromosomal abnormality in the chronic phase of chronic myeloid leukemia (CML). Clinical case Reports. Nov 19 2015 PMID 2678434

Bansal P, Osman D, Gan G, Simon GR, Boumber Y. Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. *Frontiers in Oncology* 6 (2016). PMID 27200298.

Bansal P, Rusthoven C, Boumber Y, Gan GN. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope. *Future oncology (London, England)* . PMID 27467543

Bansal P, Osman D, Simon G, Gan GN, Boumber Y Recent advances in immunotherapy in NSCLC. *Frontiers in oncology* May 2016 PMID 27200298.

Hu S, **Bansal P**, Lynch D, Hernandez CMR, Dayao Z. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature. *Journal of Medical Case Reports*. Dec 20 2016 PMID 27998299

Castresana D, **Bansal P**, Vasef MA, Kapoor V, Leone C, Quintana D. Aggressive lymphoma presenting as dysphagia: A rare cause of dysphagia. *Clinical case repots*. March 13 2017. PMID 28469848

Marchio S, **Bansal P**, Pasqualini R, Arap W. An antivascular vaccine to boost self-immunity and strike the tumor. *Proceedings of National Academy of Science*. Apr 18 2017 PMID 28400521

Patt YZ, Murad W, Fekrazad M, Baron A, **Bansal P**, Boumber Y, Steinberg K, LEE S-J, Bedrick E, Du R, Lee FC. INST OX-05-024: First Line Gemcitabine, Oxaliplatin and Erlotinib for Primary Hepatocellular Carcinoma (HCC) and Bile Duct Cancers (BDC): A multicenter Phase II Trial. *Cancer Medicine*. Aug 11 2017. PMID 28801995

PATT YZ, Hernandez RC, Fekrazad H, **Bansal P**, Lee FC. Phase II trial of sorafenib in combination with capecitabine in patients with hepatocellular carcinoma: INST 08-20. *The Oncologist* June 1 2017. PMID 28687627

Araujo Mino EP, Patt YZ, Murray-Crezan C, Hanson JA, **Bansal P**, Liem BJ, Rajput A, Fekrazad MH, Heywood G, Lee FC. Phase II trial using a combination of Capecitabine, Oxaliplatin and Celcoxib with concurrent Radiation for newly diagnosed Resectable Rectal cancer. *The Oncologist* November 20 2017. PMID 29153865

Hilal T, **Bansal P**, Kelemen K, Slack J. Nivolumab associated bone marrow necrosis. *Annals of oncology* February 1 2018. PMID 29351576

Arora S, Velichinskii R, Lesh WR, Ali U, Kubaik M, **Bansal P**, Borghaei H, Edelman MJ, Boumber Y- Existing and emerging role for checkpoint Immunotherapy in solid tumors- Advances in therapy October 2019 Volume 36, Issue 10 pp 2638-2678. PMID 31410780

Qeadan F; **Bansal P**; Hanson JA; Beswick E “The MK2 pathway is linked to G-CSF, cytokine production and metastasis in gastric cancer: a novel intercorrelation analysis approach” Journal of translational medicine volume 18, Article number: 137 (2020) PMID 32216812

Clinical Trials- Role Primary Investigator and director of clinical research New Mexico Cancer Center

GLOW8951-CL-0302- A phase 3, global, multi-center, double blind, randomized, efficacy study of Zolbetuximab (IMAB362) plus CAPOX versus Placebo plus CAPOX as first line Treatment of subjects with Claudin (CLDN) 18.2- Positive, Her 2 negative, locally Advanced unresectable metastatic gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

IMMU-132-06- A phase II open Label, study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum Based regimen or Anti PD-1/PD-L1 based immunotherapy. NCT 01631552

ANCERS-2- A Prospective observational study examining the clinical utility of CANscript in routine clinical practice.

PICI0009- An exploratory Biomaarker Study of Checkpoint inhibitors (PD-1, PD-L1 and CTLA-4) used as monotherapy or in combination in patients with malignancies that have FDA recommended indications for immunotherapy.

EMERALD- Phase 3 Trial of Elacestrant Vs standard of care for treatment of ER+/Her2- advanced breast cancer. NCT 03778931

EMERALD 2- Efficacy and safety of Durvalumab alone or combined with Bevacizumab in high risk of recurrence HCC patients after curative treatment (EMERALD-2) NCT 03847428

COSMIC 312 Study of cabozantinib in combination with atezolizumab versus sorafenib in page subjects with advanced HCC who have not received previous systemic anticancer therapy NCT 03755791

EV 302- Enfortumab Vedotin and pembrolizumab, with or without chemotherapy, versus chemotherapy alone and untreated locally advanced or metastatic urothelial cancer. NCT 04223 856

Book Chapters

Williamson EA, Wray JW, **Bansal P**, Hromas R. Overview for the histone codes for DNA repair. Prog Mol Biol Transl Sci. 2012;110:207-27.

Posters/Abstracts

Bansal, P., Rabbara, V. Utility of a simple tool to improve patient health and commonly monitored health markers *at HSTVA*: 8 August 2011: 22nd annual caring for frail elderly; Columbia, MO.

Choudhary A, Hinds AM, Uhlich RM, Ashraf I, Siddique S, **Bansal P**, Arif M, Ibdah JA, Bechtold M Sa1371 Early Aggressive Fluid Resuscitation for Acute Pancreatitis-Is It Time for Large Multicenter Randomized Trial?. 1 May 2013 Gastroenterology

Bansal P., Rabinowitz I, Boumber Y, Bansal D. Cost of colon cancer care – Results of national inpatient sample data analysis. January 2017 ASCO GI.

Bansal D, **Bansal P**, Kapoor V- Pancreatic cancer cost-of-care in inpatient setting. SGIM October 2017

Kapoor V, **Bansal P**, Rabinowitz I- Waldenstroms macroglobulinemia with light chain deposit disease- AMA September 2017 oral presentation

KZ Win, H Kang, **Bansal P**, HM Alqam, C Arana Yi Increased frequency of arterial thrombosis among patients with MPN living at an elevation of 5000 feet above sea level and beyond. Blood (Suppl 1), 5282-5282

